Wednesday, July 15, 2026

4:45 PM - 5:30 PM

---

Details

The past decades have witnessed the tremendous progress cancer precision medicine, in particular for treating cancers bearing oncogenic drivers. Thus far, over 100 molecularly targeted anticancer drugs have been approved for clinical use, and are benefiting a large population of cancer patients. Despite all these advancements, targeted anticancer therapies remain being challenged by limited response rate and frequently occurred drug resistance. Facing these challenges, we took an integrative approach to gain in-depth insights into the heterogeneous property of human cancers. We are particularly interested to understand how the oncogenic drivers are interplaying with downstream effectors to drive malignant growth. These efforts have allowed us to identify the specifically-coupled oncogenic drivers and the downstream transcription factors in different cancer context, which can be used as molecular biomarkers informing patient stratification, response assessment and drug resistance management. These insights have largely facilitated the in-house drug innovation, which led to the discovery of over 10 innovative drug candidates currently undergoing clinical trials in China and overseas. Among them, Glumetinib, a highly-specific c-Met inhibitor, has been approved for market in both China and Japan for treating non-small-cell lung cancer harboring MET exon 14 skipping mutations and SAF-189s, an ALK inhibitor, have completed the phase III trial in treating ALK-positive non-small-cell lung cancer and filed NDA in China. Both drugs showed the potential as best-in-class, further highlighting the importance of precision medicine-guided drug innovation.